|
IRF2BP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.40519999975086E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.5224999999619E-06 |
| Normal-vs-Stage2 |
7.584100E-04 |
| Normal-vs-Stage3 |
1.14610000379045E-08 |
| Normal-vs-Stage4 |
1.91520000003553E-06 |
| Stage1-vs-Stage2 |
8.557800E-01 |
| Stage1-vs-Stage3 |
7.269600E-02 |
| Stage1-vs-Stage4 |
1.757170E-01 |
| Stage2-vs-Stage3 |
1.519010E-01 |
| Stage2-vs-Stage4 |
2.263000E-01 |
| Stage3-vs-Stage4 |
9.840800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.04520000221831E-08 |
| Normal-vs-AfricanAmerican |
3.545900E-02 |
| Normal-vs-Asian |
4.63279999995958E-06 |
| Caucasian-vs-AfricanAmerican |
1.970390E-01 |
| Caucasian-vs-Asian |
5.332400E-01 |
| AfricanAmerican-vs-Asian |
1.220770E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.29879999994409E-07 |
| Normal-vs-Female |
1.01090000037551E-07 |
| Male-vs-Female |
9.424000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.42419999999521E-05 |
| Normal-vs-Age(41-60Yrs) |
2.45529999665095E-08 |
| Normal-vs-Age(61-80Yrs) |
1.72789999997036E-06 |
| Normal-vs-Age(81-100Yrs) |
3.508100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.980300E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.202200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.799000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.598800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.942400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.233800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.344680E-03 |
| Classical-VS-Follicular |
9.408200E-01 |
| Classical-VS-Other |
9.970600E-01 |
| Classical-VS-Normal |
1.00199999997219E-06 |
| Tall-VS-Follicular |
1.083320E-03 |
| Tall-VS-Other |
6.563700E-02 |
| Tall-VS-Normal |
1.8224000086775E-09 |
| Follicular-VS-Other |
9.843600E-01 |
| Follicular-VS-Normal |
1.645150E-04 |
| Other-VS-Normal |
7.372100E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.69330000524093E-08 |
| Normal-vs-N1 |
3.4424000316946E-09 |
| N0-vs-N1 |
5.439500E-02 |
|
|
